CollPlant Biotechnologies today announced that it will report financial results for the full year ended December 31, 2022, on March 29, 2023, before the market open.
| - Conference call to be held on March 29, 2023 at 10:00 am U.S. EDT - REHOVOT, Israel, March 14, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the full year ended December 31, 2022, on March 29, 2023, before the market open. The Company will then host a conference call and webcast to discuss its financial results along with corporate updates on March 29th at 10:00 am Eastern Time. Conference call information To participate in the conference call, please use the dial-in information below: U.S. investors: 1-877-407-9716 Investors outside of the U.S.: 1-201-493-6779 Conference ID: 13736701 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the scheduled call start time: https://callme.viavid.com/viavid/?callme=true&passcode=13728588&h=true&info=company&r=true&B=6 Submit questions to management in advance of the call To ask management a question ahead of the call, please email John Mullaly at LifeSci Advisors LLC up until 24 hours before the event at jmullaly@lifesciadvisors.com. Webcast information To participate in listen-only mode and to view slides corresponding to the company conference call, please visit the News & Events section of the CollPlant Investor Relations website where a link will be posted. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website for a limited time. About CollPlant CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company’s products are based on its rhCollagen (recombinant human collagen) produced with CollPlant’s proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. In 2021 CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit http://www.collplant.com Contacts CollPlant: Investors:
SOURCE CollPlant | ||
Company Codes: NASDAQ-NMS:CLGN |
View original content:
